• 1.川北醫(yī)學院附屬醫(yī)院普外三科(四川南充 637000);;
  • 2.川北醫(yī)學院附屬醫(yī)院普外一科(四川南充 637000);

目的探討趨化因子受體CXCR4和CCR7在甲狀腺癌中的表達及其臨床病理意義。方法選取2006～2009年期間在我院行手術治療的甲狀腺癌患者55例和2009年在我院行手術治療的甲狀腺腺瘤患者30例，采用免疫組織化學染色SP法檢測甲狀腺癌及甲狀腺腺瘤組織中的CXCR4和CCR7的表達。結果CXCR4和CCR7在甲狀腺癌中的表達陽性率均明顯高于甲狀腺腺瘤(P lt;0.01)。CXCR4和CCR7在臨床分期為Ⅲ+Ⅳ期的甲狀腺癌患者中的表達陽性率均明顯高于臨床分期為Ⅰ+Ⅱ期者(P lt;0.05); CCR7在有淋巴結轉移的甲狀腺癌中的表達陽性率明顯高于無淋巴結轉移者(P lt;0.05)，而CXCR4的表達陽性率與甲狀腺癌患者有無淋巴結轉移無關(P gt;0.05); CXCR4和CCR7在甲狀腺癌組織中的表達陽性率與甲狀腺癌患者的年齡和性別均無關(P gt;0.05)。在甲狀腺癌中，CXCR4陽性表達和CCR7陽性表達呈正相關(rs=0.491，P=0.000)。結論CXCR4和CCR7協(xié)同參與了甲狀腺癌的進展，可作為判斷甲狀腺癌預后的指標； CCR7高表達提示甲狀腺癌容易發(fā)生淋巴結轉移。

引用本文： 熊斌,王崇樹. 趨化因子受體CXCR4和CCR7在甲狀腺癌中的表達及其臨床病理意義. 中國普外基礎與臨床雜志, 2011, 18(12): 1301-1304. doi: 復制

1. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001, 410(6824): 5056.
2. 蔡偉, 劉丹丹, 康驊, 等. ET方案新輔助化療對乳腺癌組織中CXCR4表達的影響及臨床意義 [J]. 中國普外基礎與臨床雜志, 2010, 17(8): 812815, 823.
3. 邱明遠, 李健文, 鄭民華. CXCR4和CCR7在腫瘤中的進展研究 [J]. 中國癌癥雜志, 2010, 20(30): 222226.
4. 熊斌, 王崇樹. SDF1/CXCR4及CCL19/21CCR7與腫瘤的關系 [J]. 腫瘤預防與治療, 2011, 24(2): 131133.
5. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors [J]. J Histochem Cytochem, 2004, 52(6): 821831.
6. Yasuoka H, Kodama R, Hirokawa M, et al. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis [J]. BMC Cancer, 2008, 8: 274282.
7. 關海霞, 單忠艷, 米小軼, 等. 普遍食鹽碘化前后甲狀腺癌發(fā)病變化的11年病理資料分析 [J]. 中國醫(yī)科大學學報, 2006, 35(3): 284285.
8. 劉小華, 張敬杉, 陳金劍, 等. 甲狀腺乳頭狀癌中央?yún)^(qū)淋巴結清掃術臨床分析 [J]. 湖南醫(yī)學, 2010, 21(20): 5859.
9. 沈強. 甲狀腺癌頸淋巴結清掃術的幾點看法 [J]. 外科理論與實踐, 2009, 14(4): 379381.
10. Torregrossa L, Faviana P, Filice ME, et al. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin3 and Hector battifora mesothelial cell1 [J]. Thyroid, 2010, 20(5): 495504.
11. 蔚青, 金曉龍, 葉蕾, 等. IL13和CXCR4在甲狀腺乳頭狀癌中的表達及其相關性 [J]. 中華內(nèi)分泌外科雜志, 2010, 4(2): 7375.
12. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2mediated tumor metastasis [J]. Cancer Cell, 2004, 6(5): 459469.
13. Sutton A, Friand V, BruléDonneger S, et al. Stromal cellderived factor1/chemokine (CXC motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion [J]. Mol Cancer Res, 2007, 5(1): 2133.
14. Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas [J]. Oncogene, 2004, 23(35): 59585967.
15. Till KJ, Lin K, Zuzel M, et al. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes [J]. Blood, 2002, 99(8): 29772984.
16. Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in Bcell chronic lymphocytic leukemia/ small lymphocytic lymphoma [J]. Mayo Clin Proc, 2004, 79(3): 318325.
17. 馬飛, 寧力, 張穎妹, 等. 趨化因子受體CCR7促進乳腺癌細胞的趨化與侵襲 [J]. 第四軍醫(yī)大學學報, 2004, 25(20): 18831886.
18. Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis [J]. J Exp Clin Cancer Res, 2010, 29: 16.
19. Wagner PL, Moo TA, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma [J]. Ann Surg Oncol, 2008, 15(10): 28332841.
20. González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer [J]. Thyroid, 2009, 19(9): 957965.
21. 寶榮, 王佾, 張薇, 等. 甲狀腺乳頭狀癌中趨化因子受體CCR7的表達 [J]. 第三軍醫(yī)大學學報, 2010, 32(14): 15861587.
22. 王明華, 黃鐵柱, 惠震, 等. 趨化因子受體CXCR4在甲狀腺癌中的表達 [J]. 腫瘤防治雜志, 2008, 35(2): 107109.
23. Cabioglu N , Yazici M S, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer [J]. Clin Cancer Res, 2005,11(16): 56865693.
  1. 1. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001, 410(6824): 5056.
  2. 2. 蔡偉, 劉丹丹, 康驊, 等. ET方案新輔助化療對乳腺癌組織中CXCR4表達的影響及臨床意義 [J]. 中國普外基礎與臨床雜志, 2010, 17(8): 812815, 823.
  3. 3. 邱明遠, 李健文, 鄭民華. CXCR4和CCR7在腫瘤中的進展研究 [J]. 中國癌癥雜志, 2010, 20(30): 222226.
  4. 4. 熊斌, 王崇樹. SDF1/CXCR4及CCL19/21CCR7與腫瘤的關系 [J]. 腫瘤預防與治療, 2011, 24(2): 131133.
  5. 5. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors [J]. J Histochem Cytochem, 2004, 52(6): 821831.
  6. 6. Yasuoka H, Kodama R, Hirokawa M, et al. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis [J]. BMC Cancer, 2008, 8: 274282.
  7. 7. 關海霞, 單忠艷, 米小軼, 等. 普遍食鹽碘化前后甲狀腺癌發(fā)病變化的11年病理資料分析 [J]. 中國醫(yī)科大學學報, 2006, 35(3): 284285.
  8. 8. 劉小華, 張敬杉, 陳金劍, 等. 甲狀腺乳頭狀癌中央?yún)^(qū)淋巴結清掃術臨床分析 [J]. 湖南醫(yī)學, 2010, 21(20): 5859.
  9. 9. 沈強. 甲狀腺癌頸淋巴結清掃術的幾點看法 [J]. 外科理論與實踐, 2009, 14(4): 379381.
  10. 10. Torregrossa L, Faviana P, Filice ME, et al. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin3 and Hector battifora mesothelial cell1 [J]. Thyroid, 2010, 20(5): 495504.
  11. 11. 蔚青, 金曉龍, 葉蕾, 等. IL13和CXCR4在甲狀腺乳頭狀癌中的表達及其相關性 [J]. 中華內(nèi)分泌外科雜志, 2010, 4(2): 7375.
  12. 12. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2mediated tumor metastasis [J]. Cancer Cell, 2004, 6(5): 459469.
  13. 13. Sutton A, Friand V, BruléDonneger S, et al. Stromal cellderived factor1/chemokine (CXC motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion [J]. Mol Cancer Res, 2007, 5(1): 2133.
  14. 14. Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas [J]. Oncogene, 2004, 23(35): 59585967.
  15. 15. Till KJ, Lin K, Zuzel M, et al. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes [J]. Blood, 2002, 99(8): 29772984.
  16. 16. Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in Bcell chronic lymphocytic leukemia/ small lymphocytic lymphoma [J]. Mayo Clin Proc, 2004, 79(3): 318325.
  17. 17. 馬飛, 寧力, 張穎妹, 等. 趨化因子受體CCR7促進乳腺癌細胞的趨化與侵襲 [J]. 第四軍醫(yī)大學學報, 2004, 25(20): 18831886.
  18. 18. Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis [J]. J Exp Clin Cancer Res, 2010, 29: 16.
  19. 19. Wagner PL, Moo TA, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma [J]. Ann Surg Oncol, 2008, 15(10): 28332841.
  20. 20. González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer [J]. Thyroid, 2009, 19(9): 957965.
  21. 21. 寶榮, 王佾, 張薇, 等. 甲狀腺乳頭狀癌中趨化因子受體CCR7的表達 [J]. 第三軍醫(yī)大學學報, 2010, 32(14): 15861587.
  22. 22. 王明華, 黃鐵柱, 惠震, 等. 趨化因子受體CXCR4在甲狀腺癌中的表達 [J]. 腫瘤防治雜志, 2008, 35(2): 107109.
  23. 23. Cabioglu N , Yazici M S, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer [J]. Clin Cancer Res, 2005,11(16): 56865693.